Archie Sanchez, MD
Pulmonary Disease · Albuquerque, NMNPI 1891889283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 27.4% of the total. Reporting peaked in 2019 at $666 and has fallen 94.1% since, to $39 in 2025.
Across 52 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$270
- Mylan Specialty L.p.$143
- Boehringer Ingelheim$114
- Grifols USA, LLC$88
- Genentech USA, Inc.$85
- Philips North America LLC$55
- plus $230 from 10 others
What the payments were for
- Food & beverage$95597%
- Education$293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $270 |
| Mylan Specialty L.p. | 4 | $143 |
| Boehringer Ingelheim | 7 | $114 |
| Grifols USA, LLC | 5 | $88 |
| Genentech USA, Inc. | 4 | $85 |
| Philips North America LLC | 3 | $55 |
| GSK | 4 | $47 |
| Insmed, Inc. | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| AbbVie | 1 | $21 |
| Pulmonx Corporation | 1 | $18 |
| Electromed, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$125
How this compares
$985 in reported general payments places this provider in the 60th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 706 | $494,823 |
| OfevNintedanib Esylate | 32 | $433,409 |
| Spiriva RespimatTiotropium Bromide | 328 | $203,181 |
| SymbicortBudesonide/Formoterol Fumarate | 559 | $169,869 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $128,141 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 146 | $91,309 |
| NucalaMepolizumab | 17 | $83,928 |
| Spiriva HandihalerTiotropium Bromide | 90 | $65,261 |
| Breo ElliptaFluticasone/Vilanterol | 137 | $60,105 |
| Arnuity ElliptaFluticasone Furoate | 121 | $35,009 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $32,821 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 176 | $26,282 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 542 | $21,329 |
| DuleraMometasone/Formoterol | 27 | $17,347 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $12,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $114 | $727,899506 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $47 | $719,5781,065 claims |
| AstraZenecaSymbicort | $270 | $169,869559 claims |
| Grifols USA, LLCProlastin C | $88 | $128,14112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Albuquerque
- Lana Melendres GrovesAlbuquerque$1.1M
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Sivakumar NagarajuAlbuquerque$5K
- Ronald BronitskyAlbuquerque$4K
- Daniel NazonAlbuquerque$2K
- Sarah MedrekAlbuquerque$2K
- James BradleyAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.